BMY: Bristol-Myers Squibb Company - Summary | Jitta

Bristol-Myers Squibb Company

NYSE:BMY

Price
$77.59
Loss Chance
40.6%
6.36JITTA SCORE
60.93%Under Jitta Line
Jitta Ranking
6 / 1,170
136 / 5,115
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (54)
Recent Business Performance (73)
Financial Strength (59)
Return to Shareholders (78)
Competitive Advantage (78)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Key Stats
Jitta Score
Jitta Line
6.36
60.93%
1.97
113.33%
2.08
143.87%
Pharmaceuticals
6.68
8.06%
3.48
64.19%
7.11
26.95%
COMPANY DESCRIPTION
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.